5'-O-Phenylacetyluridine and Therapeutic Uses

JP2023551467A5Active Publication Date: 2024-12-06PHARMA CINQ LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532125
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-01
Filing Date
2021-11-30
Publication Date
2024-12-06
Estimated Expiration
2041-11-30

AI Technical Summary

Technical Problem

Existing treatments for conditions like hepatic encephalopathy and inherited disorders of the liver nitrogen cycle face challenges in effectively delivering therapeutic agents such as phenylacetic acid and uridine, leading to dose-limiting side effects and inefficiencies in plasma concentration, while also failing to address neuroinflammation and mitochondrial dysfunction.

Method used

The compound 5'-O-phenylacetyluridine (PAU) is developed to co-deliver phenylacetic acid and uridine, enhancing plasma concentration and providing neuroprotection by scavenging ammonia and mitigating metabolic imbalances, with a formulation that avoids excessive sodium intake and improves delivery to the bloodstream.

Benefits of technology

PAU effectively increases plasma uridine levels and phenylacetic acid concentrations, offering improved therapeutic benefits including neuroprotection and anti-inflammatory effects, while reducing sodium intake and overcoming delivery limitations of previous agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

5'-O-phenylacetyluridine effectively delivers both phenylacetic acid and uridine to a subject and can be used to treat hepatic encephalopathy and inherited disorders of the hepatic nitrogen cycle.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Phenyleacetic acid and its precursor phenylbutyric acid have important therapeutic uses, exploiting its activity as an ammonia scavenger for the elimination of excess ammonia in conditions such as hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle. Furthermore, the additional activities of phenylacetic acid as a molecular chaperone to alleviate protein misfolding in the endoplasmic reticulum and as an inhibitor of histone deacetylation have been exploited for therapeutic benefit in a variety of other diseases and disease models.

[0002] In conditions such as hepatic encephalopathy, neuroinflammation and decreased mitochondrial function are also involved, so excess ammonia is not the only factor in the onset and progression of the disease. The pyrimidine nucleoside uridine has broad anti-inflammatory activity both throughout the body and in the brain, providing support to cells, including neurons, with defects in mitochondrial electron transport and oxidative phosphorylation. Oral 2',3',5'-tri-O-acetyluridine increases plasma uridine more effectively than oral uridine itself, in part due to the dose-limiting side effects of oral uridine. Summary of the Invention [Means for solving the problem]

[0003] The present invention provides the compound 5'-O-phenylacetyluridine.The present invention provides a method for treating or preventing a condition selected from the group consisting of hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle in a subject, comprising administering to the subject an amount of a compound of the present invention effective to treat the disorder.The present invention also provides a compound of the present invention for use in treating or preventing a condition selected from the group consisting of hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle, or for the manufacture of a medicament for treating or preventing the condition.Furthermore, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.

[0004] The compound 5'-O-phenylacetyluridine (PAU), when administered orally, has been found to increase plasma uridine more effectively than uridine itself and to deliver phenylacetic acid to the bloodstream more effectively than phenylbutyric acid (a precursor that is preferred over phenylacetic acid as a drug due to the unpleasant odor of phenylacetic acid and is approved by the FDA for use as an ammonia scavenger). [Brief explanation of the drawings]

[0005] [Figure 1] 1 is a graph showing plasma uridine in mice after oral administration of 5'-phenylacetyluridine. [Figure 2] 1 is a graph showing plasma uracil in mice after oral administration of 5'-phenylacetyluridine. [Figure 3] 1 is a graph showing plasma uridine plus uracil in mice following oral administration of 5'-phenylacetyluridine. DETAILED DESCRIPTION OF THE INVENTION

[0006] As used herein, the transitional phrase "comprising" is open-ended. Claims utilizing this term may contain elements in addition to the elements recited in such claim. Thus, for example, a claim may be read to include a therapeutic regimen that also includes other therapeutic agents or therapeutic viral doses not specifically recited therein, so long as the recited elements or their equivalents are present.

[0007] Abbreviation: PAU or 5'-PAU: 5'-O-phenylacetyluride, also known as 5'-phenylacetyluridine PA: Phenylacetate PB: Phenylbutyrate NaPB: Sodium phenylbutyrate DMF: Dimethylformamide TLC: Thin-layer chromatography DMSO: Dimethyl sulfoxide HPMC: Hydroxypropylmethyl cellulose LPS: Lipopolysaccharide TNF: Tissue necrosis factor

[0008] [ka]

[0009] In addition to providing therapeutic benefits from the simultaneous delivery of uridine and phenylacetic acid, there is an important safety factor realized by using uridine in combination with phenylacetic acid, as uridine can attenuate metabolic imbalances caused by phenylacetic acid or its precursor, phenylbutyric acid.

[0010] Any conventional disorder characterized by the potential benefits conferred by phenylacetic acid and uridine can be treated or prevented in mammalian subjects according to the methods, compounds for use, uses, and pharmaceutical compositions of the present invention. Such conditions are selected based on any of several known activities and mechanisms of action of phenylacetic acid or its precursor, phenylbutyric acid, and also point to the broad tissue-neuroprotective and tissue-protective activity conferred by therapeutic doses of uridine. In one embodiment, hepatic encephalopathy is treated with 5'-phenylacetyluridine, where the phenylacetic acid moiety scavenges excess circulating and tissue ammonia associated with this condition, and uridine provides direct neuroprotective activity against the neuroinflammation and mitochondrial dysfunction that also characterize hepatic encephalopathy. Hepatic encephalopathy of all severity levels, from severe crises to minimal clinical symptoms, is treated with 5'-phenylacetyluridine. In severe hepatic encephalopathy, phenylacetyluridine is administered at doses ranging from 1 to a maximum of 9 grams per square meter of body surface area, one to three times per day, with the dose selected depending on the severity of ammonia excess in a particular patient.

[0011] Pulmonary artery remodeling in right ventricular failure and pulmonary hypertension involves pathological metabolic remodeling affecting the heart and pulmonary arteries, resulting in excessive aerobic glycolysis, similar to the Warburg effect in many cancers. Phenylacetic acid inhibits pyruvate carboxylase, partially alleviating pathological aerobic glycolysis. Furthermore, uridine improves inotropy in pressure-overloaded myocardium. Therefore, 5'-phenylacetyluridine, either as a single agent or in combination with uridine triacetate to adjust the uridine / phenylacetic acid ratio, provides more complete protection of the right ventricle in pulmonary hypertension than either agent alone. Right ventricular failure is the leading cause of death in people with primary pulmonary hypertension. For the treatment of pulmonary hypertension, doses of 5'-phenylacetyluridine ranging from 1 to 5 grams per square meter of body surface area are administered one to three times daily.

[0012] In accordance with the present invention, the compound may be administered to any mammalian subject. In one embodiment, the mammalian subject is a human subject. Any conventional route of administration may be utilized in accordance with the present invention. Preferably, the compound is administered orally. One skilled in the art can determine the dosage to optimize the dosage for a particular patient. Typically, the compound is administered orally to a human patient at a dose of 1 to 5 grams per square meter of body surface area. Typically, the dose is administered 1 to 3 times per day.

[0013] PB is typically administered to patients as the sodium salt (Buphenyl®) at doses of 5–25 g / day. Because sodium contains 12% sodium on a weight / weight basis, a 10 g / day NaPB treatment results in a sodium intake of 1.2 g. The recommended daily intake of sodium is 2.3 g, and excessive sodium intake is associated with increased incidence of hypertension, myocardial infarction, and stroke (Strazzullo, D'Elia et al. 2009; Frieden and Briss 2010). One objective of the present invention is to provide a biologically active derivative of PB in a form that does not add excessive sodium intake. This is achieved by esterification with uridine.

[0014] Glutamine depletion due to PB is an additional metabolic defect in mammals without urea cycle disorders or excessive levels of ammonia. Glutamine depletion and the resulting ammonia loss can lead to pyrimidine (uridine and cytidine) deficiency because glutamine is required for pyrimidine synthesis. Pyrimidine synthesis can be altered by glutamine or dietary protein levels (Monks, Chisena et al. 1985; Nelson, Qureshi et al. 1993; Zaharevitz, Grubb et al. 1993). The use of PB-related derivatives esterified with uridine provides uridine and thus prevents uridine deficiency.

[0015] The present invention will be better understood by reference to the following examples, which illustrate, but do not limit, the invention described herein. [Example] [Example]

[0016] Preparation of 5'-O-phenylacetyluridine 1. Preparation of 2',3'-O-cyclohexylidene uridine

[0017] [ka]

[0018] Uridine (50 g, 205 mmol) was dissolved in anhydrous DMF (250 mL) and a catalytic amount of para-toluenesulfonic acid (1.8 grams) was added with stirring at room temperature under argon. After 20 minutes, 31 mL, or 2.0 equivalents, of 1,1-dimethoxycyclohexane was added. The reaction mixture was stirred overnight at room temperature under argon. Completion of the reaction was confirmed by TLC (EtOAc, Rf = 0.2), and 250 mL of methanol was added and then evaporated twice. The crude reaction mixture was purified by flash chromatography using silica gel and ethyl acetate to give 33 grams of the desired product (50% yield). 1H NMR (400MHz, DMSO-d6) δ1.34~1.69 (m, 10H), 3.55 (wide width s, 2H) 4.03~4.05 (m, 1H), 4.73 (d, 1H, J=3.6Hz), 4.86~4 .88(m,1H), 5.06(s,OH), 5.61(d,1H,J=8.1Hz), 5.82(dd,1H,J=2.6,7.0Hz), 7.76~7.80(m,1H), 11.35(s,NH)

[0019] 2. Preparation of 2',3'-O-cyclohexylidene-5'-O-phenylacetyluridine

[0020] [ka]

[0021] Under argon, 2',3'-O-cyclohexylideneuridine (26.0 g, 84.4 mmol) was dissolved in 250 mL of anhydrous CHCl, 125 mL of pyridine was added, and the mixture was cooled to 0 °C. Phenylacetyl chloride (16 mL, 1.2 equiv.) was then added dropwise over 30 min. The reaction mixture was stirred at 0 °C for 4 h and at room temperature for an additional 4 h. Completion of the reaction was verified by TLC (EtOAc, Rf = 0.6). The reaction was quenched with methanol and evaporated to dryness. The residue was dissolved in 500 mL of EtOAc and washed with 0.1 N HCl, 0.05 N HCl, water, saturated NaHCO, and finally water. The crude product was purified by flash chromatography using silica gel and 50% EtOAc / hexane to give 30 g of the desired product (85% yield). 1 H NMR(400MHz,DMSO-d6)δ1.33~1.69(m,10H), 3.69(s,2H), 4.19~4.24(m,3H), 4.73~4.74(m,1H), 4.88(dd,1H,J=2 .2,6.6Hz), 5.61(d,1H,J=8.1Hz), 5.77(d,1H,J=1.9Hz), 7.24~7.32(m,5H), 7.60(d,1H,J=8.1Hz), 11.42(s,NH).

[0022] 3. Preparation of 5'-O-phenylacetyluridine

[0023] [ka]

[0024] 2',3'-O-Cyclohexylidene-5'-O-phenylacetyluridine (32.80 g, 77.1 mmol) was dissolved in 300 mL of a 1:1 mixture of formic acid and water. The reaction mixture was heated at 65-70°C for 4 hours, and consumption of the starting material was confirmed by TLC (ethyl acetate). Water and formic acid were removed by evaporation under vacuum. The crude product was dissolved in water (250 mL) and evaporated to dryness twice. Purification by flash chromatography using silica gel and ethyl acetate afforded 15.1 g (56%) of the desired product. Attempts to recrystallize the product from the solvents ethyl acetate / hexane, ethyl ether / hexane, methanol / hexane, ethanol / hexane, ethanol / ethyl ether, acetone / hexane, ethanol / ethyl ether, and methanol / ethyl ether were unsuccessful. Analysis by LC-MS showed λ 230 It was shown that 92% of the total absorbance at 1000 kJ / min corresponded to the product. 1 H NMR(400MHz,DMSO-d6)δ3.71(ABq,2H), 3.85~4.05(m,3H), 4.15~4.30(m,2H), 5.28(d,OH,J=5.1Hz), 5.43(d,OH, J=6.5Hz), 5.61(d,1H,J=8.1Hz), 5.72(d,1H,J=5.1Hz), 7.24~7.31(m,5H), 7.46(d,1H,J=8.1Hz), 11.35(s,NH). Melting point 55~57℃ [Example]

[0025] Plasma uridine and uracil pharmacokinetics after oral administration of 5'-O-phenylacetyluridine (PAU) Chemicals: HPMC (hydroxypropyl methylcellulose; SIGMA-Aldrich, cat. no. H3785, CAS 9004-65-3), 5'-O-phenylacetyluridine (PAU, lot 432-132) Vehicle: Aqueous HPMC (0.75%) was used as the suspension medium for oral administration. Dosage formulation: PAU was added to 0.75% HPMC and homogenized to eliminate clumps. The suspension was adjusted to the desired volume and concentration and sonicated to disaggregate any small remaining clumps into fine particles. The suspension was stored at 4°C until use. The suspension was used within 24 hours of preparation. Dosing: Mice were force-fed at 0.02 ml / g body weight to receive a dose of 587 mg / Kg PAU (molar equivalent to 400 mg / kg uridine). Animals: Female CD-1 mice.

[0026] [Table 1]

[0027] The overall initial design for the experiment involved force-feeding groups of six mice with PAU followed by blood samples at several time points (three mice were exsanguinated at two time points (15 and 60 min) and three mice were exsanguinated at two other time points (30 and 120 min). Each experiment included an HPMC (vehicle only) time point in three mice to establish a baseline for blood uridine.

[0028] [Table 2]

[0029] Blood samples were collected into plasma separator tubes, which were centrifuged immediately after collection, and aliquots of plasma were frozen for subsequent processing. The plasma was then deproteinized, and uridine and uracil were quantified by liquid chromatography with UV absorbance detection and mass spectrometry.

[0030] Because uracil is the first product in the enzymatic degradation of uridine, delivery of uridine into the bloodstream was assessed by monitoring plasma uridine and the total amount of uridine and uracil [uridine + uracil]. Mice convert administered uridine to uracil more rapidly and extensively than humans, and therefore uridine + uracil provides a better indicator of dosing and pharmacokinetic translation to humans than measurements of uridine alone.

[0031] Plasma uridine, uracil, and [uridine + uracil] concentrations after administration of PAU are shown in Figures 1, 2, and 3, respectively.

[0032] Delivery of phenylacetic acid to the bloodstream after oral administration of PAU was also evaluated. Sodium phenylbutyrate is used clinically as an ammonia scavenger in hepatic encephalopathy or genetic nitrogen cycle disorders, and as a chaperone or histone deacetylase inhibitor. It is largely metabolized by beta-oxidation in the liver to phenylacetic acid, which mediates the therapeutic benefits of phenylbutyric acid. PAU was administered orally at a dose equimolar to 200 mg / kg sodium phenylbutyrate. Female BALB / c mice (n = 3-5 per group) received the test compound p.o. and plasma was obtained 30 minutes later by retroorbital exsanguination. A table summarizing the comparative bioavailability of PAU and sodium phenylbutyrate derivatives shows the maximum concentrations (C ) achieved in serum after equimolar oral administration of these compounds. Max ) is used as an index of bioavailability. An equimolar dose of uridine was used as a comparison for the efficiency of delivery of uridine to the blood circulation by oral administration of PAU.

[0033] [Table 3] Plasma concentration units are micromoles per liter (μM) NaPB = sodium phenylbutyrate PB = phenylbutyrate PA = phenylacetic acid PAU = 5'-O-phenylacetyluridine

[0034] Oral PAU was substantially more effective at increasing plasma phenylacetic acid concentrations than an equimolar dose of oral sodium phenylbutyrate, resulting in more than three-fold higher circulating phenylacetic acid concentrations 30 minutes after administration. Furthermore, PAU increased plasma uridine and uracil more effectively than an equimolar dose of oral uridine. [Example]

[0035] Anti-inflammatory effects of 5'-O-phenylacetyluridine (PAU) Injection of lipopolysaccharide (LPS), a component of bacterial cell walls, has been used as a model of inflammation. The inflammatory cascade, if uninhibited, can lead to cell and organ damage. Tissue necrosis factor alpha (TNFα) is potently induced during inflammation, and attenuating this response may be protective in a number of diseases, including rheumatoid arthritis, psoriasis, vasculitis, and Alzheimer's disease.

[0036] Female BALB / c mice (41 weeks old, n = 7–8 per group) were treated with vehicle (0.75% HPMC) or PAU po and then 30 min later administered LPS (2.5 mg / kg ip). Mice were sacrificed 1 h after LPS administration, and blood was collected for plasma TNFα measurement.

[0037] [Table 4] + indicates p<0.05 compared to vehicle control.

[0038] PAU exerts a significant anti-inflammatory effect on the LPS-induced increase in plasma TNFα.

Claims

1. The compound, 5'-O-phenylacetyluridine.

2. 2. The compound of claim 1 for use in the treatment or prevention of a condition in a mammalian subject, wherein the condition is selected from the group consisting of hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

3. 3. The compound for use according to claim 2, which is administered orally to a mammalian subject.

4. 3. The compound for use according to claim 2, wherein the mammalian subject is a human subject.

5. 5. The compound for use according to claim 4, which is administered orally to a human subject.

6. The compound for use according to claim 5, administered at a dose of 1 to 5 grams per square meter of body surface area, administered 1, 2 or 3 times daily.

7. 2. The compound of claim 1 for use in the manufacture of a medicament for treating or preventing a condition in a mammalian subject, wherein the condition is selected from the group consisting of hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

8. 8. The compound for use according to claim 7, wherein the medicament is formulated for oral administration to a mammalian subject.

9. 8. The compound for use according to claim 7, wherein the mammalian subject is a human subject.

10. 10. The compound for use according to claim 9, wherein the medicament is formulated for oral administration to a human subject.

11. The compound for use according to claim 10, wherein the medicament is formulated for administration at a dosage of 1 to 5 grams of compound per square meter of body surface area, administered 1, 2 or 3 times daily.

12. A pharmaceutical composition comprising a pharma- ceutical acceptable carrier and a compound according to claim 1 in an amount effective for treating or preventing a condition in a mammalian subject, said condition being selected from the group consisting of hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

13. 13. The pharmaceutical composition of claim 12, formulated for oral administration to a mammalian subject.

14. The pharmaceutical composition of claim 12, wherein the mammalian subject is a human subject.

15. 15. The pharmaceutical composition of claim 14, formulated for oral administration to a human subject.

16. 16. The pharmaceutical composition of claim 15, formulated for administration of the compound at a dosage of 1 to 5 grams per square meter of body surface area, administered 1, 2 or 3 times daily.

17. A method for producing 5'-O-phenylacetyluridine, comprising the steps of: (a) combining uridine and 1,1-dimethoxycyclohexane under conditions to produce 2',3'-O-cyclohexylidene uridine; (b) combining the 2',3'-O-cyclohexylidene uridine with phenylacetyl chloride under conditions to produce 2',3'-O-cyclohexylidene-5'-O-phenylacetyl uridine; (c) dissolving the 2',3'-O-cyclohexylidene-5'-O-phenylacetyluridine in a solution of formic acid and water and heating the solution to form 5'-O-phenylacetyluridine; The method comprising:

18. The method of claim 17, wherein in step (a), uridine is dissolved in dimethylformamide (DMF) and para-toluenesulfonic acid prior to the addition of 1,1-dimethoxycyclohexane.

19. The method of claim 17, wherein in step (b), 2',3'-O-cyclohexylideneuridine is dissolved in CH 2 Cl 2 and pyridine is added prior to the addition of phenylacetyl chloride.

20. The method of claim 17, wherein in step (c), the solution is heated to about 65°C to about 70°C.